einstein (São Paulo). 19/Dec/2023;21:eAO0486.
Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen
DOI: 10.31744/einstein_journal/2023AO0486
Highlights
The overall incidence of febrile neutropenia in the study population was 13.4% (31 cases)
Brand-name docetaxel (Taxotere®) use was the only factor associated with the occurrence of febrile neutropenia.
No statistically significant differences in progression-free survival rates between brand-name and generic docetaxel.
ABSTRACT
Objective:
To assess the incidence of febrile neutropenia without primary granulocyte colonystimulating factor prophylaxis in patients undergoing chemotherapy with adjuvant docetaxel and cyclophosphamide, and to evaluate the toxicity profile of brand-name docetaxel (Taxotere®) and the generic formulation.
Methods:
This retrospective study was conducted using data obtained from electronic medical records of patients treated at a Brazilian cancer center. Patients with breast cancer who underwent adjuvant treatment between January 2016 and June 2019 were selected. Data were analyzed using chi-square and Fisher correlation of variables, and multivariate analyses were adjusted for propensity score.
Results:
A total of 231 patients with a mean age of 55.9 years at the time of treatment were included in the study. The majority (93.9%) had luminal histology, 84.8% were at clinical stage I, and 98.2% had a good performance status. The overall incidence of febrile neutropenia in the study population was 13.4% (31 cases). The use of brandname docetaxel (Taxotere®) was the only factor associated with febrile neutropenia occurrence (OR= 3.55, 95%CI= 1.58-7.94, p=0.002).
Conclusion:
In patients with breast cancer who require treatment with adjuvant docetaxel and cyclophosphamide regimen, the toxicity profile differs between brand-name and generic docetaxel. Regardless of the formulation used, the incidence of febrile neutropenia was less than 20%, which may allow for the omission of primary prophylactic granulocyte colony-stimulating factor use in this setting.
[…]
295
